Combined Vildagliptin and Metformin Exert Better Cardioprotection than Monotherapy against Ischemia-Reperfusion Injury in Obese-Insulin Resistant Rats

Nattayaporn Apaijai\textsuperscript{1,2}, Kroekkiat Chinda\textsuperscript{1,2}, Siripong Palee\textsuperscript{1,5}, Siriporn Chattipakorn\textsuperscript{1,3}, Nipon Chattipakorn\textsuperscript{1,2,4*}

1 Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, 2 Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, 3 Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai, Thailand, 4 Biomedical Engineering Center, Chiang Mai University, Chiang Mai, Thailand, 5 School of Medicine, Mae Fah Luang University, Chiang Rai, Thailand

Abstract

**Background:** Obese-insulin resistance caused by long-term high-fat diet (HFD) consumption is associated with left ventricular (LV) dysfunction and increased risk of myocardial infarction. Metformin and vildagliptin have been shown to exert cardioprotective effects. However, the effect of these drugs on the hearts under obese-insulin resistance with ischemia-reperfusion (I/R) injury is unclear. We hypothesized that combined vildagliptin and metformin provide better protective effects against I/R injury than monotherapy in obese-insulin resistant rats.

**Methodology:** Male Wistar rats were fed either HFD or normal diet. Rats in each diet group were divided into 4 subgroups to receive vildagliptin, metformin, combined vildagliptin and metformin, or saline for 21 days. Ischemia due to left anterior descending artery ligation was allowed for 30-min, followed by 120-min reperfusion. Metabolic parameters, heart rate variability (HRV), LV function, infarct size, mitochondrial function, calcium transient, Bax and Bcl-2, and Connexin 43 (Cx43) were determined. Rats developed insulin resistance after 12 weeks of HFD consumption. Vildagliptin, metformin, and combined drugs improved metabolic parameters, HRV, and LV function. During I/R, all treatments improved LV function, reduced infarct size and Bax, increased Bcl-2, and improved mitochondrial function in HFD rats. However, only combined drugs delayed the time to the first VT/VF onset, reduced arrhythmia score and mortality rate, and increased p-Cx43 in HFD rats.

**Conclusion:** Although both vildagliptin and metformin improved insulin resistance and attenuate myocardial injury caused by I/R, combined drugs provided better outcomes than single therapy by reducing arrhythmia score and mortality rate.

Introduction

Long-term high-fat diet consumption is known to cause obesity, insulin resistance, and cardiac dysfunction [1], and have been shown to increase the risk of having ischemic heart disease [2]. While revascularization is the goal of myocardial ischemia treatment, reperfusion therapy is known to induce reperfusion injury and lead to greater myocardial damage. This adverse effect has been shown to be even more severe in obese insulin resistance, resulting in increased infarct size and increased myocardial susceptibility to ischemia-reperfusion (I/R) injury [3,4]. I/R injury has been shown to associate with fatal cardiac arrhythmias [5]. Cardiac mitochondrial damage has been implicated as one of the major factors responsible for myocardial cell death from I/R injury [6]. Several lines of evidence showed that increased intracellular and mitochondrial calcium accumulation can trigger cell apoptosis [6,7]. Previous studies also demonstrated that decreased Connexin 43 (Cx43), the principal gap junction protein, is found in acute myocardial infarction [8]. Many studies demonstrated that loss of Cx43 expression in the heart could result in a markedly increase in incidence of arrhythmia [9,10].

Several anti-diabetic drugs including dipeptidyl peptidase 4 (DPP-4) inhibitors and metformin have been shown to exert cardioprotective effects in addition to their glycemic control [11,12]. A recent study reported the beneficial effects of combined DPP-4 inhibitor and metformin on metabolic parameters in type 2 diabetes [13].
Figure 1. Effects of HFD consumption, vildagliptin, metformin, and combined drugs on HRV and echocardiographic parameters. (A) The LF/HF ratio was increased at week 8th and week 12th of HFD consumption. *p<0.05 vs. baseline, n = 11/group. (B) Vildagliptin, metformin, and combined drugs reduced the LF/HF ratio in HFD rats. *p<0.05 vs. NDV, †p<0.05 vs. HFDV, n = 11/group. (C) %FS was decreased after 12 weeks of HFD.
Vildagliptin and Metformin in Obese-Insulin Resistant I/R Heart

Plasma and cardiac malondialdehyde (MDA) level
Plasma and cardiac MDA level was determined using high performance liquid chromatography (HPLC) based assay (Thermo scientific, Bangkok, Thailand) [1]. Plasma was mixed with H₂PO₄ and thiobarbituric acid (TBA) to produce thiobarbituric acid reactive substances (TBARS). Plasma TBARS was determined from a standard curve and reported as equivalent to the MDA concentration [1].

Heart rate variability (HRV)
Lead II electrocardiogram (ECG) was recorded for 20 minutes in conscious rats using PowerLab (AD instruments, Sydney, Australia) with Chart 5.0 program. Power spectra of R–R interval variability were obtained using Fast Fourier Transform (FFT) algorithm [1,19]. High-frequency band (HF; 0.6–3 Hz), Low-frequency band (LF; 0.2–0.6 Hz), and Very low-frequency band (VLF; below 0.2 Hz) were detected and calculated as integrals under the respective part of the power spectral density function. To minimize the effect of changes in total power on the LF and HF bands, LF and HF bands were expressed as normalized units by dividing them with the total power minus VLF [19]. LF/HF ratio was analyzed using analytical program [1]. The LF/HF ratio was considered a measure of cardiac sympathovagal balance. Increased LF/HF ratio indicated depressed HRV [19].

Echocardiography
At the end of treatment, rats were subject to I/R injury protocol (Figure 1). Rats were anesthetized using Zoletil (50 mg/kg, Virbac Laboratories, Carros, France) and Xylazine (0.15 mg/kg, LaboratoriosCalier, Barcelona, Spain), intramuscularly. Zoletil is a combination of a dissociative anesthetic agent, tiletamine hydrochloride, and a tranquilizer, zolazepam hydrochloride. The onset of action is 3–5 minutes by intramuscular route. We checked the depth of anesthesia by testing the absence of eyelid reflex and the tail pinch reflex. To maintain anesthesia, we used xylazine (0.15 mg/kg) which is an α2 adrenergic receptor agonist results in sedation, analgesia, and muscle relaxation and provides a sedative effect within 1–3 hours. Tracheostomy was performed and rats were ventilated with room air from a positive pressure rodent ventilator (CWE, Inc, Ardmore, Pennsylvania, USA). Lead II ECG was recorded throughout the experiment to determine the time to the 1st ventricular tachycardia/ventricular fibrillation (VT/VF) onset, VT/VF incidence, and arrhythmia scores. Arrhythmia score was characterized in accordance with the Lambeth conventions and using a score as described by Curtis and Walker [21]. A left-side thoracotomy was performed at the fourth intercostal space, and the pericardium was incised to expose the...

diabetic patients [13]. However, the role of these drugs including combined drugs therapy on cardiac function, heart rate variability (HRV), cardiac mitochondrial function, and intracellular calcium regulation during I/R in long-term HFD-induced obese insulin resistant rats have not been investigated.

We have previously reported the protective effects of vildagliptin and metformin on metabolic parameters and LV function in obese-insulin resistant rats [14]. In the present study, we determine the effects of a DPP-4 inhibitor vildagliptin, metformin, and combined drugs on the hearts of obese-insulin resistant rats underwent I/R injury. We hypothesized that vildagliptin and metformin provide cardioprotective effects against I/R injury in obese-insulin resistant rats, and we demonstrate that combined drugs exert better cardioprotection than either single drug regimen.

Materials and Methods

Animals and diet
All experiments in this study were approved by the Faculty of Medicine, Chiang Mai University Institutional Animal Care and Use Committee ( Permit No. 29/2555), in compliance with NIH guidelines, and in accordance with the ARRIVE guidelines for reporting experiments involving animals [15]. Male Wistar rats weighing 180–200 g were obtained from the National Animal Center, Salaya Campus, Mahidol University, Bangkok, Thailand. Rats were allowed to acclimate for seven days and housed in 12/12 hour dark/light cycle with controlled temperature (25°C). They were divided into 2 groups to receive either normal diet (ND; a standard laboratory pelleted diet containing 19.8% energy from fat) or high-fat diet (HFD; a diet containing 59.3% energy from fat) [1,16]. Rats were fed with their diet for 15 weeks. At week 12, rats in each dietary group were divided into 4 subgroups to receive vildagliptin 3-mg/kg/day (Galvus, Novartis, Bangkok, Thailand) [14], metformin 30-mg/kg/day (Glucophage, Merkserono, Bangkok, Thailand) [14], combination of vildagliptin and metformin, or vehicle (0.9% normal saline solution in an equal volume) for another 21 days via gavage feeding. Body weight and food intake were recorded weekly, and blood samples were collected from the tail vein at baseline, 12th week, and at the end of treatment (15th week). HRV was determined at baseline, 4th week, 8th week, 12th week, and 15th week (the end of pharmacological interventions).

Metabolic parameters
Plasma glucose, total cholesterol, and triglyceride levels were determined using a commercial colorimetric assay kit (Erba Diagnostics Mannheim GmbH, Mannheim, Germany) [16]. Plasma HDL level was determined using a commercial colorimetric assay kit (Biovision, California, USA) [1], and plasma LDL level was calculated using Friedewald equation [17]. Plasma insulin level was determined using a commercial sandwich ELISA kit (LINCO research, Missouri, USA) [1]. The Homeostasis Model Assesment (HOMA) index was used to assess insulin resistance. Increased HOMA index indicates a higher degree of insulin resistance [18].

consumption.*p<0.05 vs. ND, n = 11/group. (D) LVEF was decreased after 12 weeks of HFD consumption.*p<0.05 vs. ND, n = 11/group. (E) Vildagliptin, metformin, and combined drugs increased %FS in HFD rats. *p<0.05 vs. HFDV, n = 11/group. (F) Vildagliptin, metformin, and combined drugs increased LVEF in HFD rats. *p<0.05 vs. HFDV, n = 11/group.
doi:10.1371/journal.pone.0102374.g001
heart. Left anterior descending (LAD) coronary artery was identified and ligated at approximately 2 mm distal to its origin [5,22]. The end of a ligature was passed through a small vinyl tube, which is used to occlude the LAD by pulling the thread. ST elevation was used to confirm ischemia. The heart was subject to ischemia for 30 minutes, then the ligature was loosened for 120 minutes.

Left-ventricular (LV) function

The right carotid artery was identified and the pressure-volume (P-V) catheter (Sciense, Ontario, Canada) was inserted and advanced into the left ventricle to determine the cardiac function during I/R injury. Heart rate (HR), end-systolic pressure (ESP), end-diastolic pressure (EDP), maximum pressure (Pmax), minimum pressure (Pmin), dP/dtmax, dP/dtin, stroke work (SW), and stroke volume/body weight (SV/BW) were determined prior to I/R injury protocol, at the end of occlusion, and at the end of reperfusion using analytical software program (Labscribe, Dover, New Hampshire, USA).

Infarct size determination

After 150 minutes of I/R period, the heart was excised and mounted on the modified Langendorff apparatus via the aorta. Cold saline solution was used to flush out the blood, after which the LAD was re-occluded and 1-ml of 0.5% (w/v) Evans blue dye was injected to define the area at risk. Evans blue dye stained the perfused myocardium, whereas the LAD occlusion area did not stain with Evans blue dye, after which the heart was sliced into pieces with approximately 1-mm thickness for each slice and incubated with 1% buffered 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma-Aldrich, St. Louis, Missouri, USA), followed by placing them in 10% formalin overnight [5,22]. The infarct and remote areas were determined using the image tool software version 3.0. The infarct size was calculated depending on the weight of each slice according to Reis et al.’s formula [5,11,23].

Determination of cardiac mitochondrial function

For mitochondrial study, mitochondria were obtained from the ischemic myocardium and remote myocardium from fresh hearts. Ischemic area was obtained from left ventricular apex and remote area was obtained from right ventricle. The heart was minced and homogenized in the mitochondrial isolation buffer, pH 7.2, containing 300 mM sucrose, 0.2 mM EGTA, 5 mM TES. Homogenates was centrifuged at 800 g, 4°C for 5 min. The supernatant was collected and centrifuged at 8800 g, 4°C for 5 min. Then, the mitochondrial pellet was resuspended in the mitochondrial isolation buffer and centrifuged at 8800 g, 4°C for 5 min. The mitochondria were collected and the protein concentration was determined by the bicinchoninic acid method [22]. Cardiac mitochondrial function was assessed by determining cardiac mitochondrial reactive oxygen species (ROS) production, cardiac mitochondrial membrane potential change, and cardiac mitochondrial swelling [11,14,24].

Cardiac mitochondrial ROS production. Cardiac mitochondria were incubated with 2 μM DCFH-DA dye at 25°C for 20 minutes. The dye was excited at λex 485 nm and detected at λem 530 nm using fluorescent microplate reader (BioTek Instruments, Winooski, Vermont, USA). An increase in the fluorescent intensity indicated an increased mitochondrial ROS production [1,11,24].

Cardiac mitochondrial membrane potential changes. Cardiac mitochondrial membrane potential changes were determined using 5-μM JC-1 dye as described previously [1,24]. In brief, cardiac mitochondria were incubated with JC-1 at 37°C for 30 minutes. JC-1 monomer form (green fluorescent) was excited at λex 485 nm and detected at λem 530 nm using fluorescent microplate reader (BioTek Instruments, Winooski, Vermont, USA). An increase in the red/green fluorescent intensity ratio indicates cardiac mitochondrial membrane depolarization [1,11,24].

Cardiac mitochondrial swelling. Cardiac mitochondria were incubated with 1.5-mM respiration buffer containing 100 mM KC1, 10 mM HEPES, 5 mM KH2PO4, and the absorbance was determined using a spectrophotometer as described previously [1,24]. Cardiac mitochondrial swelling is indicated by a decrease in the detected absorbance [1,11,24].

Cardiac mitochondrial morphology. Cardiac mitochondria were fixed with 2.5% glutaraldehyde in a 0.1-M phosphate buffer overnight and post fixed in a 1% cacodylate-buffer osmium tetroxide for 2 hours, then dehydrated with graded series of ethanol [24]. Cardiac mitochondria were embedded in Epon-Araldite, cut with a diamond knife, and stained with uranyl acetate and lead acetate[24]. Cardiac mitochondrial morphology were detected using a transmission electron microscope [24].

| Table 1. Effects of HFD consumption on metabolic parameters at baseline and 12-week after HFD consumption. |
|-----------------------------------------------|
| Metabolic parameters                         | Baseline | Week 12 |
|                                              | ND       | HFD    | ND       | HFD    |
| Body weight (g)                              | 191±2    | 190±9  | 480±10*  | 595±28* |
| Food intake (g/day)                          | 26±1     | 29±1   | 29±2     | 26±2   |
| Plasma insulin (ng/ml)                       | 1.8±0.2  | 1.7±0.3| 1.6±0.5  | 4.2±0.7* |
| Plasma glucose (mg/dl)                       | 130±9    | 135±6  | 131±6    | 137±8   |
| HOMA index                                   | 15±2     | 14±3   | 14±4     | 35±1.9* |
| Plasma total cholesterol (mg/dl)             | 41±5     | 42±4   | 41±2     | 53±3*   |
| Plasma triglyceride (mg/dl)                  | 70±6     | 72±8   | 80±8     | 87±5    |
| Plasma HDL (mg/dl)                           | 9.6±1    | 8.3±0.8| 10.7±1   | 7.4±1.7* |
| Plasma LDL (mg/dl)                           | 17.4±1   | 19.4±0.8| 14.3±1.3| 28.2±1.7* |
| Plasma MDA (μmol/ml)                         | 2.9±0.2  | 3.1±0.1| 3.3±0.2  | 6.4±0.1* |

ND = normal diet, HFD = high-fat diet. *P<0.05 vs. Baseline, †P<0.05 vs. ND week 12.
doi:10.1371/journal.pone.0102374.t001
Western blot analysis

The myocardial tissues for western blot study was obtained from the fresh heart at the end of the I/R protocol. The ischemic myocardium was obtained from the left ventricular apex and intact myocardium was obtained from the right ventricle. Myocardial protein extracts were prepared by a homogenization of nitrogen-frozen myocardial tissues (ischemia and remote area) in a 300-μl extraction buffer containing 20-mM Tris-HCl (pH 6.0), 1-mM Sodium orthovanadate, 5-mM Sodium fluoride, and protease inhibitor. Total protein concentration was determined using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, California, USA). Fifty to 80 μg of total protein were mixed with loading buffer (5% betamercaptoethanol, 0.05% bromophenol blue, 75 mM Tris-HCl (pH 6.8), 2% SDS and 10% glycerol), and loaded onto the 10% SDS-Acrylamide gels. Proteins were transferred to polyvinylidene difluoride (PVDF) membrane in a glycine/methanol transferred buffer [5,22] in a Wet/Tank blotting system (Bio-Rad Laboratories, Hercules, California, USA). Membranes were blocked in 5% skim milk in Tris-Buffered Saline and Tween (TBST) buffer. Western blot analysis for Bax, Bcl-2, total Connexin-43, and Connexin43 phosphorylated at Ser368 was done in myocardial tissues. Membranes were exposed to mouse polyclonal anti-rat Bax and Bcl-2 (1:1000 dilution, Santa Cruz Biotechnology, Dallas, Texas, USA); Phospho-Cx43(Ser368), Cx43 (1:1000 dilution, Cell Signaling Technology, Danvers, Massachusetts, USA). Bound antibody was detected by horseradish peroxidase conjugated with anti-rabbit IgG (1:2000 dilution, Cell Signaling Technology, Danvers, Massachusetts, USA). The membranes were developed using the Amersham enhanced chemiluminescence Prime Western Blotting Detection Reagent (GE healthcare, Buckinghamshire, UK) and densitometric analysis was carried out [5].

Ventricular cardiomyocyte isolation

A separated group of thirty-two male Wistar rats was used in the intracellular calcium transient study. Rats were anesthetized by intraperitoneal injection of thiopental (1 ml/kg, Research institute of antibiotics and biotransformation, Prague, Czechoslovakia), and 0.2-ml heparin (LEO pharma, Ballerup, Denmark) was injected into the femoral vein. The heart was excised quickly with decent length of aorta and mounted on the cannula and tied with suture. The blood was washed out with solution 1 (Tyrode’s solution and 750 μM CaCl₂) then switched to solution 2 (Tyrode’s solution and 100 μM ethylene glycol tetraacetic acid (EGTA) for 4 minutes, and switched to solution 3 (Tyrode’s solution, 100 μM CaCl₂, and 1 mg/ml collagenase) for 10 minutes. The ventricles were cut and triturated in solution 3 at 37°C for 30 minutes, and were then filtered with a nylon mesh. The cells were left to settle down for 10 minutes and solution 3 was removed. Cells were resuspended in solution 4 (Tyrode’s solution, 0.5 mM CaCl₂, and 1% BSA) for 10 minutes. Cells were resuspended in 10 ml of solution 5 (Tyrode’s solution, 1 mM CaCl₂) and were ready for calcium transient study [22].

Intracellular calcium transient

The measurement of cardiomyocyte calcium transient was performed using a modified method from Wongchareonnet al. [25] as described previously [22]. Isolated cardiomyocytes were incubated with 25-μM Fura-2/AM (Sigma Chemical, St. Louis, Massachusetts, USA) in 37°C, 5% CO₂, for 30 minutes. Fura-2 was excited at ultraviolet light wavelength of 340 nm and 387 nm by monochromator from xenon arc lamp controlled by a microfluorometry system (OSP 100-CA, Olympus, Tokyo, Japan). The excitation light was directed into an inverted microscope (IX-
The emitted fluorescent intensity from Fura-2 was detected at wavelength 500 nm and digitized at 200 Hz. The ratio of fluorescent emission of two wavelengths was recorded as the index of intracellular calcium. The intracellular calcium transient peak amplitude and decay rate were measured during 1-Hz field-stimulation with a 10-ms twice-threshold strength square-pulse wave [22]. After baseline recording, 2-mM hydrogen peroxide (H2O2) was applied onto cardiomyocytes to induce oxidative stress (mimicking the ischemic process), after which the ratio of fluorescent emission of two wavelengths was recorded to determine the differences on intracellular calcium transient under oxidative stress condition among cardiomyocytes taken from the hearts of rats treated with vildagliptin, metformin, combined drugs, and vehicle.

Statistical Analysis
Data were expressed as mean ± SEM. One-way ANOVA followed by Fisher’s least significant difference post hoc was used to test the different among the group. Mortality rate and VT/VF incidence were analyzed using Chi-square test. Mitochondrial function was analyzed using Kruskal-Wallis H followed by Mann-Whitney U test. \( P<0.05 \) was considered statistical significant.

Results
Effects of metformin and vildagliptin on metabolic parameters
At baseline, metabolic parameters were not different between ND and HFD group (Table 1). After 12 weeks of HFD consumption, the body weight, plasma insulin, plasma cholesterol, plasma MDA levels and HOMA index were increased in HFD rats, compared with ND rats (Table 1). Vildagliptin, metformin, and combined drugs reduced plasma insulin, plasma total cholesterol, plasma MDA levels and HOMA index in HFD rats, compared with ND rats (Table 1). Vildagliptin, metformin, and combined drugs reduced plasma insulin, plasma total cholesterol, plasma LDL, plasma and cardiac MDA levels and increased plasma HDL level in HFD rats, compared with HFD rats treated with vehicle (HFDV) (Table 2). No difference on these parameters was found between monotherapy and combined drugs.
Table 3. Effects of metformin, vildagliptin, and combination of vildagliptin and metformin on cardiac function before I/R injury (n = 11/group).

| Cardiac function | NDV    | NDVM | NDM  | NDCHF | HFDC  | HFDV  |
|------------------|--------|------|------|-------|-------|-------|
| Heart rate (bpm) | 237 ± 12 | 213 ± 12 | 213 ± 12 | 213 ± 12 | 213 ± 12 | 213 ± 12 |
| ESP (mmHg)      | 85 ± 6  | 85 ± 6 | 85 ± 6 | 85 ± 6 | 85 ± 6 | 85 ± 6  |
| EDP (mmHg)      | 10 ± 1   | 10 ± 1 | 10 ± 1 | 10 ± 1 | 10 ± 1 | 10 ± 1   |
| SV/BW (mL/g)    | 1.06 ± 0.12 | 1.06 ± 0.12 | 1.06 ± 0.12 | 1.06 ± 0.12 | 1.06 ± 0.12 | 1.06 ± 0.12 |
| LF/HF ratio     | 0.72 ± 0.28 | 0.72 ± 0.28 | 0.72 ± 0.28 | 0.72 ± 0.28 | 0.72 ± 0.28 | 0.72 ± 0.28 |

Effects of metformin and vildagliptin on HRV

At baseline, the LF/HF ratio was not different between ND and HFD rats (Figure 1A). The LF/HF ratio was increased after 8 weeks of HFD consumption (Figure 1A). After treatment, the LF/HF ratio was not different in ND groups (Figure 1B). Treatments with vildagliptin, metformin, and combined drugs significantly reduced the LF/HF ratio in HFD rats (Figure 1B), indicating an improved cardiac sympathovagal balance in HFD rats.

Effects of metformin and vildagliptin on left ventricular function prior to I/R

At baseline, %FS and LVEF were not different between ND and HFD. We found that %FS and LVEF were decreased after 12 weeks of HFD consumption, compared with ND (Figure 1C–D). After treatment, vildagliptin, metformin, and combined drugs restored %FS and LVEF in HFD rats, compared with HFDV (Figure 1E–F).

Effects of metformin and vildagliptin on arrhythmia score during I/R

Arrhythmia score tended to be higher during I/R in HFDV than NDV rats, but the value did not reach statistical significance (Figure 2A). Only HFD rats treated with combined drugs had reduced arrhythmia score (Figure 2A). The time to 1st VT/VF onset was not different between NDV and HFDV. In ND rats, time to 1st VT/VF onset was not different among different treatment groups. In HFD rats, only combined drugs delayed time to the first VT/VF onset in HFD rats (Figure 2B). We also found that HFDV rats had a higher mortality rate, compared with the NDV group (Figure 2C). The mortality rate was reduced only in ND and HFD rats treated with combined drugs (Figure 2C). We determined the levels of Cx43 phosphorylation in heart tissues since it has been shown to closely associate with arrhythmia during I/R, and found that Cx43 phosphorylation was not different among the different treatments in ND groups (Figure 2D). However, in HFD rats, the phosphorylation of Cx43 was increased only in HFD rats treated with combined drugs (Figure 2D).

Effects of metformin and vildagliptin on left ventricular function during I/R

Baseline LV function data by P-V loop assessment prior to I/R are shown in Table 3. LV function was not different among ND groups prior to I/R injury. ESP, SV/BW were decreased and EDP was increased in HFDV rats, compared with NDV group (p<0.05 vs. NDV, Table 3). All treatments increased ESP and SV/BW and reduced EDP in HFD rats (p<0.05 vs. HFDV, Table 3).

LV function data at the end of LAD occlusion are shown in Table 4. At the end of LAD occlusion, all treatments increased the dP/dt max and combined drugs also increased the ESP in ND rats, compared with the NDV group (p<0.05 vs. NDV). In HFDV rats, the HR and EDP were increased and the ESP and SV/BW was decreased (p<0.05 vs. NDV). All treatments reduced the EDP, and increased the ESP, dP/dt max, and SV/BW in HFD rats (p<0.05 vs. HFDV, Table 4).

LV function data at the end of reperfusion are shown in Table 5. At the end of reperfusion, LV function was not different among ND groups. In HFD groups, the ESP and SV/BW was decreased and the EDP was increased in the HFDV group (p<0.05 vs. NDV). All treatments reduced the EDP and increased the ESP and SV/BW in HFD rats (p<0.05 vs. HFDV, Table 5).
Effects of metformin and vildagliptin and on the infarct size

In this study, the area at risk (AAR) was not different among all groups. We found that the infarct size/AAR was increased in the HFDV group, compared with the NDV group (Figure 3A–B). All treatments reduced the infarct size in both ND and HFD rats, compared with their remote areas, indicating mitochondrial swelling. Compared to the HFDV group, all treatments could attenuate mitochondrial depolarization (Figure 4B). All treatments could attenuate mitochondrial depolarization (Figure 4B). For mitochondrial swelling assessment, we found that the absorbance was decreased in the ischemic area of both NDV and HFDV groups, compared with their remote areas, indicating mitochondrial swelling (Figure 4C). Moreover, mitochondrial swelling was significantly greater in the HFDV rats, compared to the NDV rats. All treatments increased the absorbance in both ND and HFD rats (Figure 4C).

Representative images of cardiac mitochondria from the transmission electron microscopy showed the unfolded cristae which is an indicator of mitochondrial swelling. Compared to the intact cardiac mitochondria in the remote area of the NDV rat (Figure 4D), we found that unfolded cristae were mostly found in the ischemic area of both NDV (Figure 4E) and HFDV rats (Figure 4F). Moreover, cardiac mitochondria in the remote area of the HFDV rat (Figure 4F) also had unfolded cristae compared to that in the NDV group, indicating mitochondrial swelling. The marked unfolded cristae were found in the ischemic area of HFD rats. All treatments reduced mitochondrial ROS production in the ischemic area of HFD rats (Figure 4A).

Table 4. Effects of vildagliptin, metformin, and combination of vildagliptin and metformin on cardiac function at the end of Occlusion (n = 11/group).

| Cardiac function | NDV | NDVil | NDM | NDC | HFDV | HFDVil | HFDM | HFDC  |
|------------------|-----|-------|-----|-----|------|--------|------|-------|
| Heart rate (bpm) | 214±11 | 200±12 | 227±17 | 213±12 | 266±23* | 249±14 | 243±23 | 242±26 |
| ESP (mmHg)       | 74±4 | 82±7  | 83±20 | 103±3* | 66±7* | 90±8†  | 93±6† | 90±7†  |
| EDP (mmHg)       | 15±4 | 10±1  | 11±2  | 9±2  | 26±4* | 13±2†  | 12±1† | 14±2†  |
| Pmax (mmHg)      | 95±5 | 96±9  | 99±20 | 105±3 | 106±11 | 94±8  | 102±6 | 109±10 |
| Pmin (mmHg)      | 10±2 | 5±1   | 6±1   | 12±2 | 11±3  | 9±3   | 13±2  | 14±2   |
| dP/dtmin (mmHg/s)| 7709±1049 | 12088±2244* | 12245±1716* | 13906±2385* | 4849±394 | 11060±2295† | 12040±2132† | 12565±1091† |
| dP/dtmax (mmHg/s)| 4004±475 | 4077±572 | 5724±912 | 5252±395 | 4411±561 | 3982±813 | 4005±460 | 4038±844 |
| SW (mmHg/ml)     | 10941±1492 | 12886±1162 | 12004±2505 | 13998±637 | 10020±1456 | 10620±1937 | 9776±1553 | 10237±2322 |
| SV/BW (µl)       | 1.28±0.38 | 1.58±0.19 | 1.13±0.27 | 0.89±0.20 | 0.60±0.04* | 0.89±0.16† | 0.98±0.10† | 0.93±0.08† |

*P<0.05 vs. NDV, †P<0.05 vs. HFDV. doi:10.1371/journal.pone.0102374.t005

Table 5. Effects of vildagliptin, metformin, and combination of vildagliptin and metformin on cardiac function at the end of Reperfusion (n = 11/group).

| Cardiac function | NDV | NDVil | NDM | NDC | HFDV | HFDVil | HFDM | HFDC |
|------------------|-----|-------|-----|-----|------|--------|------|-------|
| Heart rate (bpm) | 281±23 | 248±18 | 286±63 | 237±25 | 343±48 | 252±30 | 281±31 | 264±25 |
| ESP (mmHg)       | 82±3 | 82±14 | 86±30 | 96±8 | 65±4* | 91±18† | 94±6† | 97±8†  |
| EDP (mmHg)       | 9±3  | 8±2   | 11±3  | 9±3  | 23±1 * | 9±3†  | 9±2†  | 11±1†  |
| Pmax (mmHg)      | 117±8 | 126±10 | 109±19 | 97±9 | 102±10 | 116±17 | 110±5 | 123±9  |
| Pmin (mmHg)      | 7±2  | 8±2   | 8±3   | 9±4  | 10±2  | 6±2   | 10±2  | 9±2    |
| dP/dtmax (mmHg/s)| 921±533 | 12625±2759 | 10536±1899 | 10593±2807 | 8285±1089 | 9732±1806 | 10855±816 | 10776±1761 |
| dP/dtmin (mmHg/s)| 6621±657 | 6715±1673 | 6431±651 | 6551±1434 | 7858±1440 | 8777±850 | 7945±1243 | 7550±684 |
| SW (mmHg/ml)     | 11823±2519 | 13943±846 | 10847±743 | 11095±1073 | 12374±1219 | 11775±1270 | 11434±313 | 10228±414 |
| SV/BW (µl)       | 1.02±0.28 | 1.74±0.26 | 0.92±0.12 | 1.00±0.13 | 0.67±0.02* | 1.04±0.18† | 0.97±0.07† | 0.94±0.18† |

*P<0.05 vs. NDV, †P<0.05 vs. HFDV. doi:10.1371/journal.pone.0102374.t005
HFDV. All treatments prevented unfolded cristae in both ND (Figure 4F–H) and HFD rats (Figure 4K–M).

**Effects of metformin and vildagliptin on intracellular calcium transient**

Our results demonstrated that the intracellular diastolic calcium level was increased in HFDV hearts, compared with the NDV group (Figure 5A). After treated with H₂O₂, intracellular diastolic calcium level was increased in both NDV and HFDV groups, compared with their control. We found that all treatments prevented a change in the intracellular diastolic calcium under oxidative stress condition (Figure 5A).

Calcium transient amplitude was significantly decreased in the HFDV group, compared with the NDV group (Figure 5B). After treated with H₂O₂, calcium transient amplitude was not different from baseline of its own group for both NDV and HFDV rats. However, cardiomyocytes from HFD rats treated with vildagliptin, metformin, and combined drugs had a significant increase in calcium transient amplitude both at baseline and with the presence of H₂O₂ (Figure 5B).

Calcium transient decay rate was significantly decreased in the HFDV cardiomyocytes, compared with the NDV group (Figure 5C). Calcium transient decay rate in the HFDV group was not different from baseline after treated with H₂O₂. All treatments significantly increased calcium decay rate in HFDV cardiomyocytes both at baseline and with the presence of H₂O₂ (Figure 5C). Representatives of signals of intracellular calcium transients from cardiomyocytes from each group are shown in Figure 5D.

**Discussion**

Findings from the present study demonstrated that HFD caused obese-insulin resistance, increased oxidative stress level, depressed HRV, and LV dysfunction. Treatment with vildagliptin, metformin, and combined drugs improved insulin resistance, reduced oxidative stress level, improved HRV, and attenuated LV dysfunction in obese-insulin resistant rats prior to I/R. Under I/R condition, all treatments improved LV dysfunction, reduced the infarct size, prevented cardiac mitochondrial dysfunction, decreased Bax and increased Bcl-2 expression, and reduced cardiac
oxidative stress level. Furthermore, all treatments improved intracellular calcium transient regulation in the absence and presence of H₂O₂ in the obese-insulin resistant rats. However, only combined drugs could reduce the arrhythmia score, mortality rate, delayed the time to the 1st VT/VF onset, and increased Cx-43 phosphorylation.

In this study, rats developed insulin resistance after 12 weeks of HFD consumption. This finding is consistent with previous studies in which long-term HFD consumption could induce hyperinsulinemia and increased HOMA index, indicating insulin resistance, as well as oxidative stress after 12 weeks of HFD consumption [1,14,16,26]. Previous studies have shown the beneficial effects of vildagliptin and metformin on metabolic parameters [14,27,28]. Our data showed that vildagliptin and metformin improved insulin resistance and metabolic parameters as well as oxidative stress in obese-insulin resistant rats. Clinical study reported that vildagliptin in addition to metformin reduced fasting plasma insulin level and HOMA-IR in type 2 diabetic patients [13]. Our study showed that all treatment reduced plasma cholesterol levels. However, the levels of cholesterol in this study were lower than that reported in our previous study [14]. Although these differences could be due to different kits and methods used, all drugs could still decrease the cholesterol levels, compared to the control. Moreover, clinical studies as well as studies in diabetic and insulin resistant animal models reported that vildagliptin and metformin could ameliorate oxidative stress levels [14,29,30]. In the present study, rats in all treatment groups had reduced plasma MDA level (prior to I/R) and reduced cardiac MDA level (after I/R), supporting that vildagliptin and metformin improved insulin resistance and exerted an anti-oxidative stress benefit in obese-insulin resistant rats.

HRV is an indicator of cardiac sympathovagal balance [19]. Previous studies demonstrated that cardiac sympathovagal imbalance was observed in long-term HFD fed rats [14,31]. Consistent with previous studies, we found that the LF/HF ratio was increased after 8 weeks of HFD consumption, indicating cardiac

Figure 4. Effects of vildagliptin, metformin, and combined drugs on cardiac mitochondrial function and morphology. (A) Mitochondrial ROS production was increased in ischemic area of NDV and HFDV. Mitochondrial ROS production was higher in HFDV than NDV, and all treatments reduced mitochondrial ROS production. *p<0.05 vs. remote area, †p<0.05 vs. ischemic area of NDV, n = 5/group. (B) Mitochondrial membrane depolarization was found in ischemia area of NDV and HFDV, all treatment prevented mitochondrial membrane depolarization. *p<0.05 vs. remote area of NDV, n = 5/group. (C) An absorbance was decreased in ischemic area of NDV and HFDV. The reduction of absorbance was greater in HFDV than NDV, and all treatments prevented mitochondrial swelling, *p<0.05 vs. remote area of NDV, n = 5/group. (D–M) Cardiac mitochondrial morphology doi:10.1371/journal.pone.0102374.g004
sympathovagal imbalance. Vildagliptin, metformin, and combined drugs improved the HRV by decreasing LF/HF ratio in obese-insulin resistant rats. Since depressed HRV has been reported to be associated with increased oxidative stress such as an increased MDA level [32], the improved HRV in obese-insulin resistant rats by the drugs found in our study could be due to the reduced oxidative stress caused by these drugs.

Previous studies have shown that long-term HFD consumption caused LV dysfunction [14,31], and that vildagliptin and metformin could improve LV function in obese-insulin resistant rats [14]. Consistent with previous studies, we found that LV ejection fraction and fractional shortening were reduced after 12 weeks of HFD consumption. Vildagliptin and metformin improved the LV ejection fraction and fractional shortening in the present study. Moreover, we also found that these drugs reduced intracellular diastolic calcium, improved intracellular calcium transient amplitude and decay rate in obese-insulin resistant rats. These findings suggested that one of the mechanisms responsible for improved LV function by vildagliptin and metformin could be attributed to their role in the improved intracellular calcium regulation.

In the present study, vildagliptin and metformin reduced the infarct size caused by I/R injury in obese-insulin resistant rats. Chinda and colleagues reported previously that vildagliptin reduced the infarct size in swine hearts with I/R injury [11], and several studies have demonstrated that metformin also reduced the infarct size in both non-diabetic and diabetic animals [33,34,35]. Our results further demonstrated that both vildagliptin and metformin also exerted infarct size reduction benefit in the obese-insulin resistant rat model. The mechanism responsible for this benefit of both drugs could partly due to their anti-apoptotic effects as indicated by reduced Bax and increased Bcl-2 expression. Bax is a pro-apoptotic protein, whereas Bcl-2 is an anti-apoptotic protein, both of which are known to regulate apoptosis during I/R. Furthermore, we demonstrated in the present study that both metformin and vildagliptin could attenuate cardiac mitochondrial dysfunction caused by I/R injury. It has been shown previously that both Bax and Bcl-2 are associated with mitochondrial ROS level [36]. Several studies have shown that metformin improved cardiac mitochondrial function and ultrastructure in insulin resistant rats, diabetic rats, and normal rats with I/R injury [14,37,38]. In the present study, we demonstrated that vildagliptin

Figure 5. Effects of vildagliptin, metformin, and combined drugs on intracellular calcium regulation. (A) Intracellular diastolic calcium was increased in HFDV. All treatments reduced intracellular diastolic calcium in HFD rats. (B) Calcium transient amplitude was decreased in HFDV. All treatments improved calcium transient amplitude in HFD rats. (C) Calcium transient decay rate was reduced in HFDV. All treatments increased the calcium transient decay rate in HFD rats. (D) Representative calcium transient tracing for calcium transient parameters determination. *p<0.05 vs. baseline NDV, †p<0.01 vs. baseline HFDV, ‡p<0.05 vs. HFDV with H2O2 n = 8 cells/group doi:10.1371/journal.pone.0102374.g005

Vildagliptin and Metformin in Obese-Insulin Resistant I/R Heart

PLOS ONE | www.plosone.org 11 July 2014 | Volume 9 | Issue 7 | e102374
and metformin improved cardiac mitochondrial function and ultrastructure in obese-insulin resistant rats. All of these findings suggested that vildagliptin and metformin reduced the infarct size by attenuating myocardial apoptosis and cardiac mitochondrial dysfunction. The improved cardiac mitochondrial function as well as infarct size reduction could also be responsible for improved LV function during I/R.

Despite the beneficial effects of metformin and vildagliptin as a single therapy in the present study, we found that only vildagliptin and metformin giving as combined therapy reduced fatal arrhythmias as well as delayed time to the first VT/VF onset during I/R in this obese-insulin resistant rats. This arrhythmia effect could be due to the fact that only rats treated with combined metformin and vildagliptin had increased Cx43 phosphorylation. Cx 43 is a cardiac gap junction protein, and it has been shown previously that the engraftment of Cx43 expressing cells could protect the heart against the induction of ventricular tachycardia in mice with myocardial infarction model [39]. Cx 43 phosphorylation at serine 368 has been shown to protect against cardiac arrhythmias during I/R [5,40]. Our data suggested that the increased Cx43 phosphorylation by combined metformin and vildagliptin could be a mechanism responsible for arrhythmia reduction and leading to decrease arrhythmic death from I/R in obese-insulin resistant rats.

Conclusions

In conclusion, long-term HFD consumption induced obese-insulin resistance, oxidative stress, cardiac autonomic imbalance, and LV dysfunction. Vildagliptin, metformin, and combined drugs attenuated these adverse effects. Under I/R, these drugs prevented LV dysfunction and reduced infarct size, that was associated with decreased mitochondrial function, improved intracellular calcium regulation, increased anti-apoptotic protein, and reduced pro-apoptotic protein. Only combined metformin and vildagliptin exert better benefits by reduced cardiac arrhythmia score and arrhythmic death during I/R injury in obese-insulin resistant rats by increasing Cx43 phosphorylation.

Acknowledgments

The authors would like to thank Dr. Wanpitak Pongkan, Ms. Sivaporn Sweambahram and Ms. Ponglowan Sawangnoom for their technical assistance on ventricular cardiomyocyte isolation.

Author Contributions

Conceived and designed the experiments: SC NC. Performed the experiments: NA KC SP. Analyzed the data: NA KC SP SC NC. Contributed reagents/materials/analysis tools: SC NC. Wrote the paper: NA SC NC.

References

1. Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N (2013) Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. Br J Pharmacol 169: 1048–1057.
2. Shibata R, Sato K, Pimentel DR, Takemura Y, Khaira S, et al. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11: 1096–1103.
3. du Toit EF, Smith W, Müller C, Strijdom H, Stouthammer B, et al. (2008) Myocardial susceptibility to ischemic-reperfusion injury in a prediabetic model of chronic metabolic disease. Am J Physiol Heart Circ Physiol 294: H2336–2343.
4. Wensley I, Salaveria K, Bulmer AC, Donner DG, Du Toit EF (2013) Mitochondria, Structural Function, and Ischaemic Tolerance in a Rodent Model of Obesity with Insulin Resistance. Exp Physiol. (in press)
5. Surinakaew S, Kumphone S, Chattipakorn S, Chattipakorn N (2013) Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. J Cardiovasc Pharmacol 61: 131–141.
6. Honda HM, Korge P, Weiss JN (2005) Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci 1047: 248–258.
7. Di Lisa F, Bernardi P (2006) Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovasc Res 70: 191–199.
8. Jackson PE, Feng QP, Jones DL (2008) Nitric oxide depresses connexin 43 after oxidative stress in cardiac mitochondria. Mitochondrion 11: 457–466.
9. Surinakaew S, Kumphune S, Chattipakorn S, Chattipakorn N (2013) Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. J Cardiovasc Pharmacol 61: 131–141.
10. Poelzing S, Rosen G, Leder J, Gustein DE, Fishman GI, et al. (2008) Electrical remodeling contributes to complex tachyarrhythmias in connexin 43-deficient mouse hearts. FASEB J 22: 1204–1212.
11. Poelzing S, Rosenbaum DS (2004) Altered connexin 43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol 287: H1762–1770.
12. Chinda K, Palee S, Surinakaew S, Phromphuktul M, Chattipakorn S, et al. (2013) Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol 167: 451–457.
13. Whitington HJ, Hall AK, McLaughlin CP, Hauseley DJ, Yellon DM, et al. (2013) Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 27: 5–16.
14. Deroza G, Ragoneli PD, Carbone A, Fogari E, D’Angelo A, et al. (2013) Evaluation of the positive effects on insulin-resistance and beta-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmaco Res 73: 29–36.
15. Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N (2012) Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology 153: 3076–3085.
16. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
17. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502.
18. Pipatpiboon N, Pratchayarakul W, Chattipakorn N, Chattipakorn SC (2012) PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 153: 329–338.
19. Chattipakorn N, Incharoent K, Kanlop N, Chattipakorn S (2007) Heart rate variability in myocardial infarction and heart failure. Int J Cardiol 120: 209–206.
20. Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, et al. (2012) Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardio renal syndrome. Am J Physiol Heart Circ Physiol 302: H1804–1895.
21. Curtis MJ, Hancox JC, Forkas A, Wainwright CL, Stables CL, et al (2013) The Lambeth Conventions (II): Guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther 139: 213–248.
22. Palee S, Wreeeratangkul P, Chinda K, Chattipakorn SC, Chattipakorn N (2012) Mechanisms responsible for beneficial and adverse effects of rosiglitazone in a rat model of acute cardiac ischemia-reperfusion. Exp Physiol 98: 1028–1037.
23. Russ ML, Rhodes SS, Stone DF, Alldakka M, Camarra AK (2009) Comparison of cumulative planimetry versus manual dissection to assess experimental infarct size in isolated hearts. J Pharmacol Toxicol Methods 60: 275–280.
24. Thummasorn S, Kumfu S, Chattipakorn S, Chattipakorn N (2011) Granulocyte colony-stimulating factor attenuates mitochondrial dysfunction induced by oxidative stress in cardiac mitochondria. Mitochondrion 11: 457–466.
25. Wongharson W, Chen YC, Chen YJ, Chang CM, Ye H, et al. (2006) Effects of a Nae+/Ca2+ exchanger inhibitor on pulmonary vein electrical activity and ouabain-induced arrhythmogenicity. Cardiovasc Res 70: 497–508.
26. Pintana H, Apaijai N, Pratchayarakul W, Chattipakorn N, Chattipakorn SC (2012) Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci 91: 409–414.
27. Mari A, Sallas WM, Ye VL, Watson C, Ligueros-Saylan M, et al. (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90: 4898–4904.
28. Bhawan BT, Zheng D, Kuan DA, Anderson EJ, Woodlief TL, et al. (2010) Metformin Improves Insulin Signaling in Obese Rats via Reduced IKKbeta Action in a Fiber-Type Specific Manner. J Physiol 588: 4898–4904.
29. Esteghamati A, Eskandari D, Mirmiranpour H, Noshad S, Mousavizadeh M, et al. (2013) Effects of metformin on markers of oxidative stress and antioxidative reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin Nutr 32: 179–185.
30. Avila Dde L, Arasoo GR, Silva M, Miranda PH, Diniz MF, et al. (2013) Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Arch Med Res 44: 194–202.
31. Supakul I, Pintana H, Apaijai N, Chattipakorn S, Shimalapavigiyttayom K, et al (2013) Protective effects of garlic extract on cardiac function, heart rate

PLOS ONE | www.plosone.org 12 July 2014 | Volume 9 | Issue 7 | e102374
variability, and cardiac mitochondria in obese insulin-resistant rats. Eur J Nutr. (in press)

32. Pavithran P, Nandeesha H, Sathiyapriya V, Bobby Z, Madanmohan T (2008) Short-term heart variability and oxidative stress in newly diagnosed essential hypertension. Clin Exp Hypertens 30: 496–496.

33. Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiwa M, et al. (2008) Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 103: 274–294.

34. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, et al. (2009) Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104: 403–411.

35. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, et al. (2008) Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 57: 696–705.

36. Zhang Y, Dong Y, Wu X, Lu Y, Xu Z, et al. (2010) The mitochondrial pathway of anesthetic isoflurane-induced apoptosis. J Biol Chem 285: 4025–4037.

37. Barreto-Torres G, Parodi-Rullan R, Javadov S (2012) The Role of PPARalpha in Metformin-Induced Attenuation of Mitochondrial Dysfunction in Acute Cardiac Ischemia/Reperfusion in Rats. Int J Mol Sci 13: 7694–7709.

38. Whittington HJ, Hall AR, McLaughlin GP, Hausenloy DJ, Yellon DM, et al. (2013) Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 27: 5–16.

39. Roell W, Lewalter T, Nasse P, Tailini YN, Choi BR, et al. (2007) Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 450: 819–824.

40. Sriskuldee W, Nickel BE, Fandrich RR, Jiang ZS, Kardami E (2006) Administration of FGF-2 to the heart stimulates connexin-43 phosphorylation at protein kinase C target sites. Cell Commun Adhes 13: 13–19.